Patent · US Active

GPR40 agonists for the treatment of type II diabetes

US9908873B2 · kind B2 · utility

2Cited by

3References

30Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Hui Huang · Blue Bell, US
Sanath K. Meegalla · Boothwyn, US
Mark R. Player · Phoenixville, US

Key dates

Filing date	Aug 4, 2016
Grant date	Mar 6, 2018
Priority date	—
Expiry date	Aug 4, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (II) as follows:wherein R1B, R2B, R4B, WB, XB, YB, and GB, are defined herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.